Lantronix xPico 250 IoT Gateway Enables Secure Connected Healthcare Applications
Lantronix Inc. (NASDAQ: LTRX) is enhancing IoT technology for point-of-care (POC) medical diagnostic devices, responding to the rising demand driven by diseases, including COVID-19. The global POC diagnostics market is projected to grow from $43.49 billion in 2021 to $81.37 billion by 2028, with a CAGR of 9.4%. Lantronix's xPico 250 IoT gateway supports secure connectivity for rapid diagnostic testing, facilitating faster prototypes and reduced development costs for medical device developers. Their solutions aim to improve patient care and operational efficiency in health settings.
- Strong demand for POC diagnostics, with a projected market growth from $43.49 billion in 2021 to $81.37 billion by 2028.
- Lantronix's xPico 250 gateway offers secure, multi-protocol connectivity, enhancing efficiency in remote diagnostics.
- Reduction in development costs and faster time-to-market for medical device developers using Lantronix solutions.
- None.
Lantronix’s IoT Technology Integral to Development of Point-of-Care Medical Diagnostic Devices
IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM) offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware, provides IoT technologies that are driving the development of secure point-of-care (POC) connected healthcare applications for remote clinical, veterinary and environmental testing.
“In today’s world of critical medical equipment needs, we at Lantronix are dedicated to providing IoT and intelligent edge systems that enable our clients to deliver secure connected healthcare solutions for the remote diagnostics and treatment of patients,” said Jacques Issa, VP of Marketing at Lantronix Inc.
Growing Demand for Secure IoT Connected Healthcare Applications
The demand for quality POC diagnostics kits is rapidly increasing due to acute and chronic diseases worldwide, including COVID-19. According to Fortune Business Insights, the global POC diagnostics market grew 86.9 percent in 2020. It is projected to grow from
Testing units depend on secure IoT connectivity to remotely perform testing and deliver accurate results. Lantronix delivers proven IoT solutions that have pushed its medical device clients to the forefront of patient care with the development of remote diagnosis devices.
For POC medical diagnostic device developers, Lantronix benefits include:
- Accelerated timeline to deliver a prototype
- Reduced total cost of development
- Faster production and time-to-market
Case Study: Lantronix’s xPico 250 IoT Gateway Enables Connected Healthcare Application
Lantronix’s xPico 250 IoT gateway was used in the development of a rapid and sensitive molecular diagnostic device for detection of up to 32 targeted pathogens from one sample in a single run.
Challenge: Find Secure Wi-Fi and Bluetooth Connectivity in a Small Form Factor
With the mission of reinventing how rapid molecular diagnostic capabilities are applied to a variety of applications, the client’s team embarked on creating the mobile testing device for pathogens, such as COVID-19 testing. In accelerating the timeline to create a prototype and deliver the analyzer to market, the developer needed to ensure that the design would meet compliance with the FDA’s Emergency Use Authorization. The team turned to Lantronix for an affordable and compact gateway solution with Ethernet, Wi-Fi® and Bluetooth® connectivity as well as WPA-2 enterprise security.
Solution: Lantronix xPico 250 Embedded Wi-Fi and Bluetooth Combo IoT Gateway
Delivering seamless and secure Ethernet, Wi-Fi and Bluetooth connectivity, the Lantronix xPico 250 line of embedded IoT gateways enables OEMs to build and deploy smart connected products with reduced complexity and lower risk. Lantronix xPico features and benefits include:
- Highly integrated connectivity in a compact form
- Robust connectivity for reliable data access and management
- Scalable and secure cloud-based, centralized device management
- Over-the-network remote management and maintenance
- Comprehensive built-in device security, including data-at-rest protection for keys, configuration, secure boot and secure firmware over-the-air protection
Results: A Market-Ready Prototype and Speed to Market
The Lantronix xPico 250 Embedded IoT gateway gave the developer a small, secure multi-protocol connectivity solution needed for its instrument. Designed to provide portable, fast and accurate molecular diagnostic testing, its purpose is to help medical professionals save lives by testing up to 32 targeted pathogens from one sample in a single run.
The small footprint and simple workflow of the device enables testing to be performed in a variety of settings, including hospitals and laboratories, quarantine rooms, physicians’ offices, urgent care, assisted living facilities and other remote locations as needed.
About Lantronix
Lantronix Inc. is a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM), offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware.
Lantronix enables its customers to accelerate time to market and increase operational up-time and efficiency by providing reliable, secure and connected Intelligent Edge IoT and Remote Management Gateway solutions.
Lantronix’s products and services dramatically simplify the creation, development, deployment and management of IoT and IT projects across Robotics, Automotive, Wearables, Video Conferencing, Industrial, Medical, Logistics, Smart Cities, Security, Retail, Branch Office, Server Room, and Datacenter applications. For more information, visit www.lantronix.com.
Learn more at the Lantronix blog, www.lantronix.com/blog, featuring industry discussion and updates. To follow Lantronix on Twitter, please visit www.twitter.com/Lantronix. View our video library on YouTube at www.youtube.com/user/LantronixInc or connect with us on LinkedIn at www.linkedin.com/company/lantronix.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Any statements set forth in this news release that are not entirely historical and factual in nature, including without limitation statements related to our solutions, technologies and products as well as xPico 200 and the delivery of secure connected healthcare solutions for the remote diagnostics and treatment of patients, are forward-looking statements. These forward-looking statements are based on our current expectations and are subject to substantial risks and uncertainties that could cause our actual results, future business, financial condition, or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this news release. The potential risks and uncertainties include, but are not limited to, such factors as the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; the impact of the COVID-19 outbreak on our employees, supply and distribution chains, and the global economy; cybersecurity risks; changes in applicable U.S. and foreign government laws, regulations, and tariffs; our ability to successfully implement our acquisitions strategy or integrate acquired companies; difficulties and costs of protecting patents and other proprietary rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; and any additional factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, filed with the Securities and Exchange Commission (the “SEC”) on September 11, 2020, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, as well as in our other public filings with the SEC. Additional risk factors may be identified from time to time in our future filings. The forward-looking statements included in this release speak only as of the date hereof, and we do not undertake any obligation to update these forward-looking statements to reflect subsequent events or circumstances.
© 2021 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark, and xPico is a trademark of Lantronix Inc. Other trademarks and trade names are those of their respective owners.
Lantronix Media Contact:
Gail Kathryn Miller
Corporate Marketing &
Communications Manager
media@lantronix.com
949-453-7158
Lantronix Analyst and Investor Contact:
Jeremy Whitaker
Chief Financial Officer
investors@lantronix.com
949-450-7241
Lantronix Sales:
sales@lantronix.com
Americas +1 (800) 422-7055 (US and Canada) or +1 949-453-3990
Europe, Middle East and Africa +31 (0)76 52 36 744
Asia Pacific + 852 3428-2338
China + 86 21-6237-8868
Japan +81 (0) 50-1354-6201
India +91 994-551-2488
FAQ
What is the current market forecast for POC diagnostics related to Lantronix (LTRX)?
How does Lantronix support medical device developers in the IoT space?
What are the benefits of using Lantronix's xPico 250 IoT gateway for healthcare applications?
What role does IoT technology play in Lantronix's medical applications?
